ReviewDiagnostics (Basel, Switzerland)2026
From Divergent Pathogenesis to Precision Medicine: The Road to Targeted Therapy in HIV-Associated and HIV-Unrelated Diffuse Large B-Cell Lymphoma.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common and biologically heterogeneous subtype of non-Hodgkin lymphoma. While immunochemotherapy has improved outcomes, survival remains variable due to substantial molecular diversity. In people living with HIV (PLWH), DLBCL is the predominant lymphoma subtype and demonstrates more aggressive clinical behaviour, characterised by advanced-stage disease, extranodal involvement, and a potentially poorer prognosis despite antiretroviral therapy. Clarifying differences in the pathogenesis of HIV-associated and HIV-unrelated DLBCL is essential for informing precision therapies. This narrative review highlights the contrasting pathogenic mechanisms, with an emphasis on the interplay between viral oncogenesis, host immunity, and molecular alterations in HIV-associated DLBCL versus DLBCL in immunocompetent individuals. Understanding these differences is critical for refining diagnostic approaches, improving risk stratification, and identifying novel therapeutic strategies tailored to both groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.